Vanda Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Vanda Pharmaceuticals
VNDA Stock  USD 7.80  0.22  2.74%   
Vanda Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vanda Pharmaceuticals' valuation are provided below:
Gross Profit
200.3 M
Profit Margin
(0.40)
Market Capitalization
459.8 M
Enterprise Value Revenue
0.8984
Revenue
212.1 M
We have found one hundred twenty available fundamental trend indicators for Vanda Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vanda Pharmaceuticals current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 409.2 M, whereas Enterprise Value is forecasted to decline to about 98.9 M.

Vanda Pharmaceuticals Total Revenue

141.82 Million

Check Vanda Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vanda Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 M, Interest Expense of 6 M or Total Revenue of 141.8 M, as well as many indicators such as Price To Sales Ratio of 1.53, Dividend Yield of 0.0 or PTB Ratio of 0.57. Vanda financial statements analysis is a perfect complement when working with Vanda Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Vanda Stock
Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.

Vanda Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets792.4 M754.6 M394.6 M
Slightly volatile
Short and Long Term Debt Total10.2 M14.2 M12.7 M
Very volatile
Other Current Liabilities111.3 M106 M53.7 M
Slightly volatile
Total Current Liabilities120.7 M115 M61.5 M
Slightly volatile
Total Stockholder Equity650.3 M619.3 M305 M
Slightly volatile
Other Liabilities5.8 M6.1 M22.7 M
Slightly volatile
Property Plant And Equipment Net15.3 M14.6 M7.8 M
Slightly volatile
Accounts Payable4.1 M4 M4.3 M
Slightly volatile
Cash74.2 M117.7 M72.2 M
Slightly volatile
Non Current Assets Total262.4 M249.9 M97.6 M
Slightly volatile
Non Currrent Assets Other11 M10.5 M5.1 M
Slightly volatile
Other Assets103.1 M98.2 M43.4 M
Slightly volatile
Cash And Short Term Investments218.5 M430.8 M248.4 M
Slightly volatile
Common Stock Total Equity39.5 K65.5 K44.4 K
Slightly volatile
Common Stock Shares Outstanding65.2 M52.3 M72.6 M
Slightly volatile
Liabilities And Stockholders Equity792.4 M754.6 M394.6 M
Slightly volatile
Non Current Liabilities Total28.7 M15.9 M28.3 M
Slightly volatile
Other Current Assets18.6 M17.7 M10.3 M
Slightly volatile
Other Stockholder Equity461.5 M819.6 M516.2 M
Slightly volatile
Total Liabilities86.8 M135.3 M86.4 M
Slightly volatile
Property Plant And Equipment Gross29.3 M27.9 M10.2 M
Slightly volatile
Total Current Assets530 M504.7 M297.1 M
Slightly volatile
Short Term Debt3.7 M3.8 M7.8 M
Pretty Stable
Common Stock41.8 K66.7 K44.7 K
Slightly volatile
Property Plant Equipment3.5 M3 M3.7 M
Slightly volatile
Short Term Investments159.5 M313.2 M177.7 M
Slightly volatile
Net Receivables56.9 M54.2 M23.9 M
Slightly volatile
Intangible Assets137.8 M131.2 M44.8 M
Slightly volatile
Net Tangible Assets614.2 M584.9 M285.1 M
Slightly volatile
Capital Surpluse578 M789.2 M539.6 M
Slightly volatile
Long Term Investments15.2 M17.1 M18.7 M
Slightly volatile
Long Term Debt Total20 M22.5 M24.6 M
Slightly volatile
Non Current Liabilities Other10 M11 M7.7 M
Slightly volatile
Net Invested Capital465.7 M619.3 M317.1 M
Slightly volatile
Short and Long Term Debt21.6 M24.3 M26.5 M
Slightly volatile
Net Working Capital343.7 M389.7 M231.1 M
Slightly volatile
Capital Stock61.3 K66.7 K54.9 K
Slightly volatile
Capital Lease Obligations9.8 M11.1 M13.3 M
Slightly volatile

Vanda Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.8 M9.4 M4.7 M
Slightly volatile
Total Revenue141.8 M228.6 M148.4 M
Slightly volatile
Gross Profit128.6 M215.6 M135.2 M
Slightly volatile
Other Operating Expenses289.1 M275.3 M167.8 M
Slightly volatile
Research Development44.7 M85.6 M48 M
Slightly volatile
Cost Of Revenue19.2 M10.2 M20.3 M
Pretty Stable
Total Operating Expenses275.5 M262.3 M154.6 M
Slightly volatile
Total Other Income Expense Net21.4 M20.4 M6.1 M
Slightly volatile
Selling General Administrative174.5 M166.2 M98.5 M
Slightly volatile
Non Operating Income Net Other368.8 K414.9 K452.9 K
Slightly volatile
Selling And Marketing Expenses2.9 M1.7 M3.8 M
Pretty Stable
Reconciled Depreciation9.8 M9.4 M4 M
Slightly volatile

Vanda Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow164.6 M156.7 M75.9 M
Slightly volatile
Depreciation9.8 M9.4 M4.8 M
Slightly volatile
Capital Expenditures535.3 K563.5 K2.9 M
Very volatile
End Period Cash Flow74.3 M118.2 M72.4 M
Slightly volatile
Stock Based Compensation10.6 M11.2 M370.4 M
Slightly volatile
Exchange Rate Changes25.3 K46 K25.5 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.531.617.9 K
Slightly volatile
PTB Ratio0.570.5919.8856
Slightly volatile
Days Sales Outstanding60.5999.4660.9408
Very volatile
Book Value Per Share8.758.345.443
Slightly volatile
Average Payables1.7 M1.8 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.06830.07190.2225
Slightly volatile
Capex To Depreciation0.06580.06930.9775
Pretty Stable
PB Ratio0.570.5919.8856
Slightly volatile
EV To Sales1.041.097.9 K
Slightly volatile
Inventory Turnover11.475.912.8225
Slightly volatile
Days Of Inventory On Hand60.8364.03198
Slightly volatile
Payables Turnover5.742.915.4396
Slightly volatile
Sales General And Administrative To Revenue1.010.840.9541
Slightly volatile
Average Inventory1.9 M1.8 M1.9 M
Slightly volatile
Research And Ddevelopement To Revenue0.410.4313.3038
Slightly volatile
Capex To Revenue0.00270.00280.7441
Slightly volatile
Cash Per Share3.635.84.9342
Slightly volatile
Days Payables Outstanding216130212
Slightly volatile
Intangibles To Total Assets0.160.17390.0988
Slightly volatile
Current Ratio7.025.055.9794
Pretty Stable
Tangible Book Value Per Share6.96.574.661
Slightly volatile
Receivables Turnover4.614.859.4072
Slightly volatile
Shareholders Equity Per Share8.758.345.443
Slightly volatile
Debt To Equity0.01790.02070.0293
Slightly volatile
Capex Per Share0.00920.00970.0633
Pretty Stable
Average Receivables919.2 K1.7 M1.8 M
Very volatile
Revenue Per Share2.13.082.8491
Slightly volatile
Interest Debt Per Share0.10.190.2241
Pretty Stable
Debt To Assets0.02090.02170.0254
Slightly volatile
Graham Number3.343.527.1906
Pretty Stable
Operating Cycle199164183
Slightly volatile
Price Book Value Ratio0.570.5919.8856
Slightly volatile
Days Of Payables Outstanding216130212
Slightly volatile
Company Equity Multiplier1.331.42.3767
Slightly volatile
Long Term Debt To Capitalization0.00710.0080.0087
Slightly volatile
Total Debt To Capitalization0.01740.02020.0284
Slightly volatile
Debt Equity Ratio0.01790.02070.0293
Slightly volatile
Quick Ratio6.955.035.9241
Pretty Stable
Net Income Per E B T1.180.951.0821
Very volatile
Cash Ratio1.121.182.2059
Slightly volatile
Days Of Inventory Outstanding60.8364.03198
Slightly volatile
Days Of Sales Outstanding60.5999.4660.9408
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.11.191.0225
Very volatile
Price To Book Ratio0.570.5919.8856
Slightly volatile
Fixed Asset Turnover17.1814.1120.9077
Very volatile
Debt Ratio0.02090.02170.0254
Slightly volatile
Price Sales Ratio1.531.617.9 K
Slightly volatile
Asset Turnover0.290.270.3816
Pretty Stable
Gross Profit Margin0.690.850.8652
Pretty Stable
Price Fair Value0.570.5919.8856
Slightly volatile

Vanda Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap409.2 M217.9 M518.6 M
Very volatile
Enterprise Value98.9 M104.2 M434 M
Very volatile

Vanda Fundamental Market Drivers

Forward Price Earnings103.0928
Cash And Short Term Investments374.6 M

Vanda Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vanda Pharmaceuticals Financial Statements

Vanda Pharmaceuticals stakeholders use historical fundamental indicators, such as Vanda Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Vanda Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vanda Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Vanda Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vanda Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.2 M-5 M
Total Revenue228.6 M141.8 M
Cost Of Revenue10.2 M19.2 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 0.84  1.01 
Research And Ddevelopement To Revenue 0.43  0.41 
Revenue Per Share 3.08  2.10 
Ebit Per Revenue(0.18)(0.19)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HITIHigh Tide
HITIHigh Tide
BACBank of America
When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:
How To Invest In Vanda
Details
Is Vanda Stock a good investment?
Details
What is Vanda Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
(1.44)
Revenue Per Share
3.611
Quarterly Revenue Growth
0.181
Return On Assets
(0.12)
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY